<?xml version="1.0"?>
<Articles JournalTitle="Acta Medica Iranica">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Acta Medica Iranica</JournalTitle>
      <Issn>0044-6025</Issn>
      <Volume>47</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="epublish">
        <Year>2009</Year>
        <Month>04</Month>
        <Day>15</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Correlation Between Prognosis and Response to Treatment in Children with FSGS</title>
    <FirstPage>93</FirstPage>
    <LastPage>96</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Mitra</FirstName>
        <LastName>Naseri</LastName>
        <affiliation locale="en_US">Department of Nephrology, School of Medical, Mashhad University of Medical Sciences, Mashhad, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Abbas</FirstName>
        <LastName>Madani</LastName>
        <affiliation locale="en_US">Department of Pediatric Nephrology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
      </Author>
      <Author>
        <FirstName>Nematollah</FirstName>
        <LastName>Ataei</LastName>
        <affiliation locale="en_US">Department of Pediatric Nephrology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2015</Year>
        <Month>09</Month>
        <Day>28</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">To determine the prognostic value of response to treatment in patients with focal segmental glomerulo-sclerosis. FSGS includes 10-15% of idiopathic Nephrotic syndrome in children. Bulk of evidence supports disease relationship with immune system. Unfortunately, responses to immunosuppressive drugs are not desirable and progression to end-stage renal disease is common. We analyzed 62 out of 99 cases of biopsy proven idiopathic FSGS who were followed for at least 5-years or until renal failure occurred during study. Study design was historical cohort and patients were divided into two groups: exposed (resistant to treatment) and non-exposed (responsive to treatment). Correlation between prognosis and response to treatment was statistically evaluated. P-value (0.05 and relative risk ( 1 was considered significant. In 3 out of 25 steroid responsive patients (12%) and 22 out of 37 steroid resistant patients (59.5%), disease progressed to renal failure. Disease progressed to renal failure in 2 out of 11 cyclophosphamide responsive patients (18.1%), 17 out of 23 cyclophosphamide resistant patients (74.3%), and 8 out of 14 cyclosporine resistant patients (57.1%). 2 patients who responded to cyclosporine had normal renal function at the time of the last follow up. We concluded that favorable response to steroid and cyclophosphamide treatment is a protective factor against disease progression to end stage renal disease and resistance to these drugs imply a poor prognosis. For making any definite conclusion concerning response to cyclosporine treatment and prognosis, similar studies with a larger sample are required.</abstract>
    <web_url>https://acta.tums.ac.ir/index.php/acta/article/view/3553</web_url>
    <pdf_url>https://acta.tums.ac.ir/index.php/acta/article/download/3553/3529</pdf_url>
  </Article>
</Articles>
